Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma

Sunitinib is a multiple tyrosine kinase receptor inhibitor that is approved for the treatment of metastatic renal cell carcinoma (RCC). However, neither an appropriate dose nor dosing schedule of sunitinib has yet been established for patients with metastatic RCC who are on hemodialysis. Here, we re...

Descripción completa

Detalles Bibliográficos
Autores principales: Yildiz, Ibrahim, Sen, Fatma, Kilic, Leyla, Ciftci, Rumeysa, Basaran, Mert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Urological Association 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897635/
https://www.ncbi.nlm.nih.gov/pubmed/24466402
http://dx.doi.org/10.4111/kju.2014.55.1.74

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897635/
https://www.ncbi.nlm.nih.gov/pubmed/24466402
http://dx.doi.org/10.4111/kju.2014.55.1.74

Ejemplares similares